Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma

Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP

This is a multicenter randomized trial evaluating induction treatment with VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T cell lymphoma.

Induction therapy:

ARM 1: 6 Chemotherapy courses = 3 VIP alternated with 3 ABVD ARM 2: 8 Chemotherapy courses = CHOP every 21 days

Consolidation therapy:

For all patients if CR = radiotherapy 40GY / 5X1,8 GY per week

Inclusion Criteria:

• newly diagnosed untreated PTCL
• age 18 and 70 years
• performance status ≤ 2
• Ann Arbor stage I to IV
• normal cardiac ventricular ejection fraction over 50%
• normal hepatic function (asat, ALAT, PAL < 2.5 ULN)

Exclusion Criteria:

• cutaneous form of PTCL
• previous treatment
• age < 18 and > 70
• performance status > 2
• abnormal cardiac or hepatic functions
• HIV-, HCV- or HBV- positivity